CTS Corp. (CTS) Misses Q2 EPS by 1c: Lifts Outlook

CTS Corp. (NYSE: CTS) reported Q2 EPS of $0.62, $0.01 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $145 million versus the consensus estimate of $146.18 million.

GUIDANCE:

CTS Corp. sees Q3 2022 EPS of $2.40-$2.55, versus prior of $2.20-$2.45 and the consensus of $2.50. CTS Corp. sees Q3 2022 revenue of $570-600 million, versus prior of $550-$580 million and the consensus of $583.13 million.

For earnings history and earnings-related data on CTS Corp. (CTS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c